Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
432 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01396148 | A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor | completed | Phase 2 | 6 | PfizerINDUSTRY | 3 | Mar 27, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT02473952 |
| A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis |
| completed |
| Phase 2 |
| 62 |
| Grifols Therapeutics LLCINDUSTRY |
| 10 |
| Mar 5, 2019 |
| clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT00910091 | The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer | completed | Phase 2 | 73 | IpsenINDUSTRY | 12 | Jan 30, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 | clinicaltrials |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 18 | PfizerINDUSTRY | 2 | Jan 8, 2019 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT02107430 | Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 62 | SOTIO a.s.INDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00454779 | PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response | completed | Phase 2 | 113 | AmgenINDUSTRY | 9 | Oct 17, 2018 | clinicaltrials |
| NCT02594163 | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 25 | Seagen Inc.INDUSTRY | 7 | Oct 16, 2018 | clinicaltrials |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | completed | Phase 2 | 67 | Astellas Pharma IncINDUSTRY | 4 | Oct 2, 2018 | clinicaltrials |
| NCT01923168 | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | completed | Phase 2 | 340 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 14, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT01461057 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer(JOSHUA) | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 8 | Aug 9, 2018 | clinicaltrials |
| NCT01925612 | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 87 | Seagen Inc.INDUSTRY | 5 | Jun 21, 2018 | clinicaltrials |
| NCT00890825 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 12 | Jun 20, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT00360347 | A Study of Mircera in Anemic Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | — | Hoffmann-La RocheINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT02131662 | Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap(ASTEROID 1) | completed | Phase 2 | 309 | BayerINDUSTRY | 13 | Dec 8, 2017 | clinicaltrials |
| NCT00101998 | Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication | completed | Phase 2 | 233 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 26 | Aug 30, 2017 | clinicaltrials |
| NCT02016534 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | terminated | Phase 2 | 60 | AmgenINDUSTRY | 18 | Jul 2, 2017 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT02105675 | Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 60 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107391 | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer | completed | Phase 2 | 63 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107404 | Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer | completed | Phase 2 | 150 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02137746 | Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer | completed | Phase 2 | 24 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | withdrawn | Phase 2 / Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 10 | May 5, 2017 | clinicaltrials |
| NCT01740336 | A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 183 | Genentech, Inc.INDUSTRY | 8 | Apr 24, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 225 | GlaxoSmithKlineINDUSTRY | 8 | Mar 27, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer(SHINE) | terminated | Phase 2 | 960 | AstraZenecaINDUSTRY | 16 | Mar 7, 2017 | clinicaltrials |
| NCT01429064 | Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 | completed | Phase 2 | 76 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Feb 20, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT01040832 | EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 107 | EMD SeronoINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT02064725 | Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA | unknown | Phase 2 | 8 | Kevelt ASINDUSTRY | 5 | Jan 24, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials